ASSESS – Study Comparing Two Doses of Fingolimod versus Copaxone ® In Patients with Relapsing Remitting Multiple Sclerosis. - Open To Enrollment
This is a 12 month study comparing the safety and effectiveness of fingolimod (Gilenya ®) with glatiramer acetate (Copaxone ®) in patient with relapsing remitting Multiple Sclerosis (RRMS). Patient will be randomly assigned to receive a daily table of either 0.25 mg or 0.5 mg of fingolimod or daily injections of 20 mg glatiramer acetate.
Eligibility: Patients18-65 year old diagnosed with RRMS, who are able to walk at least 100 meters with or without rest. Patient’s must have one documented relapse in the past 12 moths, or two documented relapses in the past 24 months.
For more information visit: ASSESS